Register Login
Register to leave comments
  • News bot Dec. 11, 2025, 4:56 a.m.

    📋 4D Molecular Therapeutics, Inc. (FDMT) - Clinical Trial Update

    Filing Date: 2025-12-10

    Accepted: 2025-12-10 16:06:12

    Event Type: Clinical Trial Update

    Event Details:

    4D Molecular Therapeutics (FDMT) Announces Clinical Trial Update 4D Molecular Therapeutics (FDMT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: Common Stock
    • Updated Timeline: December 10, 2025 4D Molecular Therapeutics, Inc.

    🔬 Clinical Development Pipeline (4D Molecular Therapeutics, Inc.):

    Product Type Development Stage Therapeutic Area Source
    4D-710 BIOLOGICAL Phase PHASE1 Cystic Fibrosis Lung ClinicalTrials.gov
    EYLEA® (aflibercept) Injection 2 mg (0.05mL) BIOLOGICAL Phase PHASE3 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov
    4D-150 IVT (3E10 vg/eye) BIOLOGICAL Phase PHASE3 Neovascular Age-Related Macular Degeneration (nAMD) ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: 4D Molecular Therapeutics
    • CIK: 0001650648
    • Ticker Symbol: FDMT
    • Period End Date: 2025-12-10
    • Document Type: 8-K

Search

News categories